KALA BIO, INC. Net Income (Loss) Available to Common Stockholders, Diluted
KALA BIO, INC. (KALA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$1.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-19
- KALA BIO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$1.58M.
- KALA BIO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$11.15M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$1.58M 10-Q · filed 2026-08-19 | -$3.20M 10-Q · filed 2026-08-19 |
| 2025-06-30 | -$11.15M 10-Q · filed 2026-08-19 | -$20.10M 10-Q · filed 2026-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |